कैंसर विज्ञान एवं चिकित्सा

Breast cancer (BC) is one of the most heterogeneous types of cancer and is characterized by several molecular subtypes. Descriptive cross-sectional study was conducted on 137 confirmed BC cases at Tikur Anbessa Specialized Hospital (TASH) in Ethiopia from December 2015 to November 2016 to assess the biological and clinicopathological characteristics of BC in Ethiopian women patients. Socio-demographic characteristics of the study subjects was obtained with pretested structured interview and clinical data was collected from the Hospital records. Surgical specimens were analysed histopathologically with hematoxyline and eosin staining, and Immunohistochemistry analysis was conducted with specific antibodies to ER, PR and HER2. The mean and median age of the study participants were 47 and 46.7, respectively. More than 50% of the patients were categorized in the age group of 15-40. Sixty percent were in the age group of 41-100. Infiltrating ductal carcinoma was the most common type of BC (70%) in this study, followed by lobular carcinoma (8.5%). Almost all of the BC cases under study were at advanced stage of the disease: 48.5% were with stage III and 51% were grade II tumors. Half of the study participants belonged to T2 tumor size (2-5 cm) and 52.3% of the patients had axillary lymph node metastases. Sixty five percent were ER+, 58% were PR+ and 28% were HER2+. Luminal A was the most common tumor subtype (54%), followed by luminal B (22%) and TNBC (18%). Based on crude analysis, patients with family history of BC had a lesser likelihood of being ER+ as compared to those patients with no family history of BC [COR=0.10 (95% CI: 0.028, 0.34)]. None of the other risk factors were correlated with the prevalence of ER+ results. In conclusion, the age distribution of BC cases in this study suggests the need to create awareness and improvement of advanced diagnostic services and make available screening programs for younger people. In a resource poor setting like Ethiopia, the use of anti-estrogens (like tamoxifen) in treatment of BC cases with undetermined receptor status could be helpful as most BC cases are ER+ and hormonal therapy is relatively easily available.

This is a continuous investigation of a possible application of Coded Aperture (CA) for breast tumor imaging. This image formation system allows a high photon transmission, image magnification and to a lesser extent provide (limited-angle) tomographic capability. This paper describes two non-Monte Carlo methods, the first one based on a simple attractive approach called Binary Mask Shift (BMS) representing the action of a distributed source in the projective CA imaging geometry. It allows to investigate all the possible built in artefacts without the effect of solid angle. Thus, it provides understanding of the application of CA patterns in breast tumor imaging through the evaluation of their potential and their performance under a variety of imaging conditions. The second method based on Pseudo-Ray Tracing (PRT) that obtained by purely calculating the angle of incidence of each point in the object that successfully strikes an open aperture element and then hits the detector element. These methods particularly used for CA imaging investigations. Interestingly, these methods yield similar results of a similar CA pattern but takes less computing power, than using a full Monte Carlo Simulation (MCS) approach. The main results demonstrate that Modified Uniformly Redundant Arrays (MURAs) patterns of squares arrays are very promising as it produces excellent decoded images. This is attractive particularly when used for breast tumor imaging i.e. ideal for imaging small isolated sources and thus provides a good match to the imaging of Scintimammography (SM).

Hepatocellular Carcinoma (HCC) is a common type of primary liver cancer. According to the recent world cancer report, the disease ranked as the sixth most common cancer worldwide and the third largest cause of cancer-related death. Deregulation of numerous signaling pathways have been implicate in pathogenesis of HCC, including IGF, EGF/TGF, HGF/cMet, WNT, Hedgehog, notch, hippo, VEGF, PDGF, and FGF. Besides, intracellular mediators such as MAPK and PI3K/AKT/mTOR play a role in HCC development and progression. Currently sorafenib is the only molecularly targeted drug available to treat advanced HCC. It only extends survival by a matter of months. Moreover, there is no alternative agent for patients progressing under treatment with sorafenib. Thus, there remains a critical need for both continued molecular characterization and aggressive drug development. This review provided and updated appraisal of the deregulated signaling and epigenetic pathways, targeted therapeutics that is being investigated and possible challenges in drug development for HCC.